BACKGROUND: Intramedullary spinal cord tumors (IMSCTs) are rare, heterogenous lesions that are usually enhanced on preoperative magnetic resonance imaging (MRI) because of a damaged blood-brain barrier. Sodium fluorescein is a dye that accumulates in areas of the central nervous system with a damaged BBB. Given the pattern of MRI contrast enhancement of the majority of IMSCTs, the use of this fluorescent tracer could improve tumor visualization and quality of resection. In this article, we present the first experience with the application of fluorescein-guided technique for surgical removal of IMSCTs. METHODS: Eleven patients (6 men, 5 women; mean age, 50.1 years), harboring 5 ependymomas, 3 hemangioblastomas, 1 astrocytoma, 1 pilocytic astrocytoma, and 1 glioneuronal tumor forming rosettes were included. Sodium fluorescein (5 mg/kg) was injected immediately after patient intubation. Tumors were removed with microsurgical technique and standard neurophysiological monitoring, under YELLOW 560 filter (Pentero 900) visualization. Surgical reports were reviewed regarding usefulness and grade of fluorescein staining. Postoperative MRI was performed within 72 hours after surgery, and postoperative clinical outcome was registered. RESULTS: No adverse events were registered. Fluorescent staining was reported in 9 of 11 cases (82%), all of them enhancing on preoperative MRI (100% of ependymomas, 100% of pilocytic astrocytomas, 100% of hemangioblastomas). No fluorescence was reported in 1 astrocytoma and 1 glioneuronal tumor-forming rosette. Intraoperative fluorescence was considered helpful for tumor resection in 9 of 11 cases (82%). Gross total resection was obtained in 8 of 11 cases (72.7%). CONCLUSIONS: Our results suggest that fluorescein-guided surgery is a safe and effective technique that can be used during the surgical resection of IMSCTs presenting with contrast-enhancement on preoperative MRI.
BACKGROUND: Intramedullary spinal cord tumors (IMSCTs) are rare, heterogenous lesions that are usually enhanced on preoperative magnetic resonance imaging (MRI) because of a damaged blood-brain barrier. Sodium fluorescein is a dye that accumulates in areas of the central nervous system with a damaged BBB. Given the pattern of MRI contrast enhancement of the majority of IMSCTs, the use of this fluorescent tracer could improve tumor visualization and quality of resection. In this article, we present the first experience with the application of fluorescein-guided technique for surgical removal of IMSCTs. METHODS: Eleven patients (6 men, 5 women; mean age, 50.1 years), harboring 5 ependymomas, 3 hemangioblastomas, 1 astrocytoma, 1 pilocytic astrocytoma, and 1 glioneuronal tumor forming rosettes were included. Sodium fluorescein (5 mg/kg) was injected immediately after patient intubation. Tumors were removed with microsurgical technique and standard neurophysiological monitoring, under YELLOW 560 filter (Pentero 900) visualization. Surgical reports were reviewed regarding usefulness and grade of fluorescein staining. Postoperative MRI was performed within 72 hours after surgery, and postoperative clinical outcome was registered. RESULTS: No adverse events were registered. Fluorescent staining was reported in 9 of 11 cases (82%), all of them enhancing on preoperative MRI (100% of ependymomas, 100% of pilocytic astrocytomas, 100% of hemangioblastomas). No fluorescence was reported in 1 astrocytoma and 1 glioneuronal tumor-forming rosette. Intraoperative fluorescence was considered helpful for tumor resection in 9 of 11 cases (82%). Gross total resection was obtained in 8 of 11 cases (72.7%). CONCLUSIONS: Our results suggest that fluorescein-guided surgery is a safe and effective technique that can be used during the surgical resection of IMSCTs presenting with contrast-enhancement on preoperative MRI.
Authors: Ajay A Madhavan; Felix E Diehn; Jeffrey B Rykken; John T Wald; Chris P Wood; Kara M Schwartz; Timothy J Kaufmann; Christopher H Hunt; Dong Kun Kim; Laurence J Eckel Journal: Clin Neuroradiol Date: 2020-05-07 Impact factor: 3.649
Authors: Jacopo Falco; Julius Höhne; Morgan Broggi; Emanuele Rubiu; Francesco Restelli; Ignazio G Vetrano; Marco Schiariti; Elio Mazzapicchi; Giulio Bonomo; Paolo Ferroli; Karl-Michael Schebesch; Francesco Acerbi Journal: Front Oncol Date: 2022-08-09 Impact factor: 5.738
Authors: Lucas Serra Sant'Anna; Raphael Sepúlvida; Rafael Abbud; Rafael Teixeira Magalhães Leal; Marcus André Acioly Journal: Neurosurg Rev Date: 2022-05-31 Impact factor: 2.800
Authors: J J Sun; J Yang; J C Xie; Q Chang; C C Ma; M Zheng; H I Liao; T Wang; X D Chen; Y F Han; G Z Lin; T Yu; J Zhang; Y Si Journal: Beijing Da Xue Xue Bao Yi Xue Ban Date: 2019-10-18
Authors: Yash B Singh; Steve S Cho; Rachel Blue; Clare W Teng; Emma De Ravin; Love Buch; John Y K Lee Journal: Oper Neurosurg (Hagerstown) Date: 2021-02-16 Impact factor: 2.703
Authors: Alexander J Schupper; Manasa Rao; Nicki Mohammadi; Rebecca Baron; John Y K Lee; Francesco Acerbi; Constantinos G Hadjipanayis Journal: Front Neurol Date: 2021-06-16 Impact factor: 4.003
Authors: Luca Raspagliesi; Antonio D'Ammando; Matteo Gionso; Natasha D Sheybani; Maria-Beatriz Lopes; David Moore; Steven Allen; Jeremy Gatesman; Edoardo Porto; Kelsie Timbie; Andrea Franzini; Francesco Di Meco; Jason Sheehan; Zhiyuan Xu; Francesco Prada Journal: Front Oncol Date: 2021-06-21 Impact factor: 6.244